Managing moderate-to-severe paediatric asthma: a scoping review of the efficacy and safety of fluticasone propionate/salmeterol.
Paulo Márcio PitrezSira NanthapisalAna Paula Beltran Moschione CastroChirag TeliAbhijith P GPublished in: BMJ open respiratory research (2023)
FP/SAL is a reliable treatment option in patients not achieving control with ICS monotherapy or a different ICS/LABA combination. Evidence shows that FP/SAL is well tolerated and has a similar safety profile to FP monotherapy. Thus, FP/SAL provides an effective option for the management of moderate-to-severe asthma in the paediatric population.
Keyphrases
- combination therapy
- end stage renal disease
- intensive care unit
- emergency department
- ejection fraction
- newly diagnosed
- high intensity
- chronic kidney disease
- chronic obstructive pulmonary disease
- prognostic factors
- clinical trial
- early onset
- lung function
- cystic fibrosis
- allergic rhinitis
- smoking cessation
- replacement therapy